 | |
 | |
| Clinical data | |
|---|---|
| Other names | Androst-4-ene-3β,17β-diol |
| Routes of administration | Oral |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H30O2 |
| Molar mass | 290.447 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
4-Androstenediol, also known asandrost-4-ene-3β,17β-diol, is anandrostenediol that is converted totestosterone. The conversion rate is about 15.76%, almost triple that of4-androstenedione, due to utilization of a different enzymatic pathway. There is also some conversion intoestrogen, since testosterone is the metabolic precursor of the estrogens.
4-Androstenediol is closer totestosterone structurally than5-androstenediol, and hasandrogenic effects, acting as a weakpartial agonist of theandrogen receptor.[1] However, due to its lowerintrinsic activity in comparison, in the presence offull agonists like testosterone ordihydrotestosterone (DHT), 4-androstenediol hasantagonistic actions, behaving more like anantiandrogen.[1]
4-Androstenediol is very weaklyestrogenic. It has approximately 0.5% and 0.6% of theaffinity of estradiol at theERα andERβ, respectively.[2]
Patrick Arnold holds a 1999 patent on "Use of 4-androstenediol to increase testosterone levels in humans".[3]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
